Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred | Scientific Reports
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial - The Lancet Oncology
Status of adjuvant endocrine therapy for breast cancer | Breast Cancer Research | Full Text
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Cancer treatment and survivorship statistics, 2022 - Miller - 2022 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Updates in endocrine therapy for metastatic breast cancer | Cancer Biology & Medicine
Frontiers | Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
Chemotherapy Statistics | Success Rate & Cost
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
PDF) Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Breast cancer recurrence: factors impacting occurrence and survival | Irish Journal of Medical Science (1971 -)
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Figure 1 from Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. | Semantic Scholar
CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2− breast cancer: A meta‐analysis of randomized controlled trials - Wang - 2020 - The Breast Journal - Wiley Online Library
Rethinking neoadjuvant chemotherapy for breast cancer | The BMJ
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Metastatic Breast Cancer
The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer
